We attempted to determine retrospectively whether use of celecoxib or other nonsteroidal anti-inflammatory drugs as concomitant medications conferred benefit to patients with CRC who participated on clinical trials testing BRAF inhibitor-based therapies; however, incomplete data collection and heterogeneous dosing precluded this analysis. The gene discussed is BRAF; the disease is colorectal carcinoma.